Purpose Knowledge of the different usage patterns that emerge during a long-term statin therapy is limited. The aim of this study was to characterize statin use, including the rates of reinitiation after extended periods of non-use, transitions between good and poor adherence, and the effect of the length of a drug-free period on the identification of new users. Methods The study cohort comprised individuals aged 45-84 years who were identified in the Finnish prescription register as having purchased statins between 1997 and 2007. New users in 1997, including those with no statin purchases during the preceding 3 years, were followed-up until institutionalization, death, or 31 December 2007. Reinitiation rates after ≥180 days with no refill for statins were analyzed using survival analysis. Annual adherence levels and the prevalences of good (proportion of days covered ≥0.80) and poor (<0.80) adherence were calculated for ten 1-year periods following initiation. For statin users in 2007, purchases were captured over the previous 10 years. Results Based on the data extracted from the Finnish prescription register, 32,760 persons initiated statin treatment in 1997, of whom 48.1% had discontinued it for at least 180 days by the end of the follow-up period. Of the discontinuers, 46.7% restarted the treatment within 1 year and 88.7% by the end of the follow-up. Of those followed up for ≥10 years, 51.8% had ≥6 years of treatment with good adherence. In 2007, 27.7% of the initiators having no statin purchases within the previous year had refills during the preceding 10 years. Conclusion Statin use is dynamic. This should be taken into consideration in clinical practice and when studying the incidence, patterns, and health outcomes of statin use.
Introduction
Statins have been shown to reduce the risk of cardiovascular events in a wide variety of high-risk patients [1, 2] ; however, the benefits of statin therapy may be compromised because of suboptimal persistence with and/or adherence to the drug regime [3] [4] [5] . Between 25 and 50% of new statin users discontinue the therapy during the first year [6] [7] [8] [9] . A study in Finland revealed that only 44% of individuals initiating statin use in 1995 continued it for ≥10 years [9] . Subsequent analyses revealed that the pattern of statin use remained stable in the period 1995-2004, with a slight improvement in persistence rates for those initiating treatment between 1998 and 2004 [10] . Information on discontinuation rates is also important because an interruption of statin use may increase the risk of cardiovascular events and death in some patient groups [11, 12] , potentially attributable to a biologic rebound phenomenon [13] . However, studies ending the follow-up at the first extended break in refills are likely to underestimate the patient's cumulative statin exposure. In fact, studies reporting on reinitation rates indicate that the majority of those who stop statin therapy resume the use of these drugs later in their life [14, 15] .
Observational studies on statin effectiveness typically employ new-user designs, thereby restricting the study cohort to initiators. The new-user design allows the researcher to estimate the effects associated with drug initiation, to adjust for confounding due to predictors of persistence with drug therapy, and to avoid overadjustment for potential consequences of drug treatment [16] . Nevertheless, no consensus exists on the required time period without statin use prior to the first observed use. In administrative database studies, the allotted periods without any statin (or any lipid-lowering drug [4] ) dispensations prior to the cohort entry have ranged from 3-6 months [17, 18 ] to 1-3 years [3-5, 19, 20] . The choice of the length of this so-called washout period is likely to be motivated by the reimbursement, prescribing, and dispensing rules of the healthcare system through which the data for a specific study are generated. Thus, especially when studying refill patterns, it may be reasonable to select the washout period according to the characteristics of the data source; however, differences in washout periods across studies may hamper the comparison of the risk estimates of health outcomes obtained in them.
The aim of this study was two-fold: to characterize the patterns of long-term statin use, including the rates of reinitiation after extended periods of non-use and transitions between good and poor adherence, and to describe the effect of the length of drug-free period on the identification of new use, in a sample of statin initiators in Finland.
Methods

Reimbursement for and pricing of statins in Finland
In Finland, statins are available on prescription only. The National Health Insurance Scheme, run by the Social Insurance Institution of Finland (SII), provides prescription drug coverage for all of the approximately 5 million community-dwelling residents of the country [21] . The drug reimbursement system consists of three refund categories (basic, lower special, and higher special refund) that are graded according to medical criteria based on the severity of the illness and the necessity of the drug therapy [22] . Statins are reimbursed under the basic refund category, with the exception of patients entitled to the lower special refund due to dyslipidemia associated with coronary artery disease (CAD) (since 2000) or familial hypercholesterolemia. The copayment for the basic refund category was 10 euros per purchase and 50% of the balance of the remaining price until the end of 2005; for the lower special refund category, the respective figures were 5 euros and 25%. Thereafter, 42 and 72% of the price of each drug is reimbursed. The introduction of generic simvastatin in 2003 dramatically lowered the prices of simvastatin products. Beginning in October 2006, the prescribing of less expensive statins was promoted by a restriction of the reimbursement of the most expensive ones, atorvastatin and rosuvastatin. These two statins remained reimbursable only for treatment of severe disorders of lipid metabolism in high-risk patients who were not able to use less expensive statins due to intolerance or ineffectiveness [23] . In practice, users of atorvastatin and rosuvastatin were entitled to reimbursement only after they had first tried the less expensive statins.
Data sources
Since 1994, the SII has maintained an electronic pharmacy claims database called the Prescription Register. The Register contains records of all drug purchases reimbursed to residents in non-institutional settings [21] as well as data on each dispensed drug, including dispensing date, the World Health Organization Anatomical Therapeutic Chemical (ATC) classification code [24] , and quantity of drug dispensed. Information on birth and death dates and gender is available for each person filling a prescription. Persons institutionalized permanently, including those staying in public nursing homes and hospitals for >90 days without interruption, are not eligible for reimbursements, and their purchases are not registered. These individuals can be identified from a separate SII register.
Due to the reliance of this study on the data contained in the Prescription Register, the expression statin use in this report refers to the purchase of statins or the dispensing of statin prescriptions in a pharmacy. The actual use of statins could not be verified.
Study samples
There were two separate samples. The first study sample consisted of persons initiating statin therapy (ATC code C10AA) during the year 1997. We defined an initiator (new statin user) as a person being dispensed a statin prescription without having been dispensed one in the preceding 3 years (1,095 days). As a sensitivity analysis, the above definition was relaxed so that all persons with no dispensations for statins during the preceding year (365 days) were considered as initiators. The initiators were followed-up until they died, were institutionalized permanently according to the SII register, or the end-point of the follow-up was reached or 31 December 2007, whichever came first.
A drug coverage data file was created for each initiator in order to be able to identify discontinuation dates. Consecutive prescriptions were linked together based on dispensing dates and the number of days for which each prescription was written, assuming a dosage of one tablet per day. If a prescription was filled when there should have been unused tablets from the previous dispensation, we assumed the use of the new supply to begin after the end of the previous supply. Discontinuation was defined as failing to fill a prescription within 180 days of finishing the previous one. In the sensitivity analyses, this gap was defined as 90 and 270 days. According to the Finnish drug reimbursement scheme, a maximum of 3 months' supply of medication can be reimbursed at one transaction; therefore, gaps applicable in other reimbursement systems may be too short in the Finnish context. We analyzed statins as a group, and therefore considered the switching between various statins as continuation of the therapy.
Adherence was operationalized as the proportion of days covered (PDC) [25] . Based on reimbursed statin purchases and assuming a dosage of one tablet per day, we obtained the PDC with a statin for each year (365-day period) of follow-up by dividing the number of days on which the person had a statin on-hand by 365. Good adherence refers to PDC ≥0.80 [6, 26] .
The second sample included all persons who had purchased statins in 2007. For this sample, we defined new statin users by varying the requirement for the length of the period without statin dispensations prior to the first prescription in 2007 from 3 months [17] to up to 9 years. The percentages of persons misclassified were classified in each case, with those individuals with no statin dispensations during the previous ≥10 years defined as true new users.
Statistical analysis
The χ 2 square test and t test were used to compare the characteristics of those qualifying and not qualifying as statin initiators when different purchase-free gaps were employed. For the discontinuers in the 1997 sample, we estimated the distribution of the time until a person refilled a statin prescription with the Kaplan-Meier method, using SAS software (ver. 9.1; SAS Institute, Cary, NC). There was no legal requirement for approval by an ethics committee since de-identified data were used and there was no contact with individuals.
Results
Characteristics of the initiators in 1997
A cohort of 32,760 statin initiators, i.e., those with no statin purchases during the preceding 3 years and aged 45-84 years in 1997, was identified. The initiators had a mean age of 63 years and slightly less than half were male ( Table 1) . As identified in the SII Special Reimbursement Register, 10,682 (32.6%) had an established CAD and 88 (0.3%) had familial hypercholesterolemia. The initial statin was most commonly simvastatin (Table 1 ). The mean follow-up time was 8.2 ± 3.4 (standard deviation) years, with 10,357 (31.6%) being censored because of institutionalization and 2,825 (8.6%) because of death.
In the sensitivity analyses, the definition for new users was relaxed to include all those with no statin dispensations during the preceding 1-year period, resulting in the identification of 36,581 users between the ages of 45 and 84 years (Table 1) . Compared with those qualifying as initiators with the 3-year gap (Table 1) , the 3,821 persons qualifying with the 1-year but not with the 3-year gap were more commonly male (55.5%) and somewhat younger [mean age 62.3 ± 8.5 years). In addition, they initiated their statin therapy more commonly with lovastatin (23.7%) and less commonly with simvastatin (40.8%) or fluvastatin (29.0%; p values for all comparisons <0.0001).
Patterns of statin use in the 1997 cohort Of the original cohort (n=32,760), 15,759 or almost every second (48.1%) person had at least one statin-free period lasting for ≥180 days during the follow-up. There were 20,840 (63.6%) initiators with at least one 90-day statin-free gap and 13,165 (40.2%) initiators with at least a 270-day gap. Of those with 90-, 180-, and 270-day gaps, 62.4, 46.7, and 36.7% were estimated to have reinitiated statin therapy within 1 year after the end of the first gap (Fig. 1) . By the end of the follow-up, the reinitiation rates were 92.3, 88.7, and 86.2%, respectively.
Of those surviving at least 365 days following statin initiation (n=30,893), 14,886 (48.2%) had good first-year adherence (PDC ≥0.80; Table 2 ), while 2,874 (9.3%) purchased only one statin prescription by the end of the first year. The proportion of those with good adherence increased up to 58.8% by the tenth year of follow-up. The proportion of those with continuous good adherence throughout the 10-year follow-up (17.1%) was the same as the proportion of those never achieving good adherence in any of the 10 years (17.3%) (Fig. 2) . Altogether, 51.8% of those followed up for 10 years used statins with good adherence for a total of ≥6 years, and 69.2% had good adherence for ≥3 years (total number of 1-year gaps in good adherence was at most 4 and 7, respectively).
Sensitivity analyses revealed similar patterns of discontinuation, reinitiation, and adherence in the cohort identified using the relaxed definition of new use (n=36,518). The proportions of initiators with at least one statin-free period lasting 90, 180, or 270 days during the follow-up were 64.7, 49.2, and 41.1%, respectively. It was estimated that 62.8, 47.7, and 38.2% of those with 90-, 180-and 270-day gaps, respectively, restarted the therapy within 1 year after the end of the first gap. By the end of the follow-up, the estimated probabilities of reinitiation were 92.5, 89.1, and 86.8%, respectively. Of those surviving at least 1 year since initiation (n=34,517), 47.2% had good adherence and 9.7% purchased only one prescription during that year. One half (51.1%) of those followed up for ≥10 years after initiation (n=22,486) accumulated at least six 1-year periods of good adherence.
Characteristics and previous statin purchases of the initiators in 2007
In total, 520,894 Finns aged 45-84 years purchased statins in 2007. Of the 78,512 new statin users defined as those Fig. 1 Kaplan-Meier estimates of cumulative probability of reinitiating statin therapy in cohorts in which stopping therapy was defined as a tablet-free period of at least 90, 180, and 270 days, respectively, after completion of a prescription. Index dates were the dates 90, 180, and 270 days after the completion of the last prescription, respectively (Table 1) . One in five (21.0%) of the 99,348 initiators defined as those with a 1-year purchase-free period did not qualify as such when a 3-year purchase-free period was applied. These 20,836 initiators differed from those with no dispensations during the previous 3 years (Table 1) by being older (mean age 64.4 ± 9.7 years) and less commonly male (49.2%). Among this group, the initial statin was less commonly simvastatin (70.4%) and more commonly atorvastatin (11.0%) rosuvastatin (5.6%), fluvastatin (5.7%), pravastatin (4.1%), lovastatin (2.0%), or a combination of simvastatin and ezetimibe (1.2%) (p values for all comparisons <0.0001). Overall, the number of new users decreased rapidly with the increasing length of statin-free period required before the first statin purchase in 2007: 27.7% of the new users defined as those with a 1-year purchase-free period did not qualify as such when a 10-year gap was used (Fig. 3) . When a 1-year gap was used, women aged 65-84 years were somewhat more commonly (34.1%) misclassified as new users than were men of the same age (30.1%) or women and men aged 45-64 years (24.1 and 24.8%, respectively).
Discussion
Our observations based on unselected populations of statin initiators from a country with universal prescription drug coverage support the view that long-term statin use is dynamic [15] . More specifically, we observed that most statin users had at least one extended period of non-use during an average of 8.2 years of follow-up. The majority (86-92%) of those who stopped statin use, however, reinitiated it. Accordingly, almost 30% of persons with no statin purchases within 1 year preceding the initiation (a conventional definition for new use) were not statin-naive when the required period of no statin purchases was extended to the previous 10 years. Finally, while only every sixth statin initiator maintained good adherence and was therefore supposedly exposed to an optimal statin therapy throughout the whole 10-year period, every second initiator accumulated altogether ≥6 years of such exposure.
The incidence of 90-and 180-day treatment gaps and also the rates of reinitiation after the first gap were slightly higher in our study than in a Canadian study which focused on individuals who initiated statin therapy between January 1997 and June 2004 [15] . This may partly be explained by the differences in reimbursement rules affecting the refill patterns, with the typical duration of a statin prescription being 1 month in Canada and 3 months in Finland. Indeed, our sensitivity analyses showed that the estimated rates of discontinuation and reinitiation depend considerably on the gap length chosen, supporting our view that the use of shorter gap lengths in such studies may overestimate the rate of interruptions in statin use in the Finnish context. Interestingly, our estimates on discontinuation and restarting of and good adherence to statin therapy were only marginally affected by the definition of new use in 1997. However, while approximately 10% of the 1997 sample defined as new statin users with a conventional definition of no statin purchases during the preceding year had purchased statins within the previous 3 years, the respective proportion in the 2007 sample was already about 20%. In addition, the differences between those qualifying as new users with the 1-year gap but not with the 3-year gap seemed to be larger in 2007 than in 1997. One reason for the differences in the distribution of the initiating statin in 2007 may be the reimbursement restriction of atorvastatin and rosuvastatin [23] . In practice, the restriction meant that the initiators of atorvastatin and rosuvastatin with no trial with less expensive statins did not receive reimbursement for their statin and their purchases did not appear in Table 2 for the numbers of patients in the follow-up) the Prescription Register either. About half of those using atorvastatin and 40% of those using rosuvastatin in 2006 had switched to simvastatin or another less expensive statin by the end of 2007 [23] . It is possible that not all statin purchases by the switchers were captured in the Prescription Register and that some switchers may have appeared as new users in 2007. Therefore, the rates of misclassification with the shortest washout periods might be exceptionally high in 2007. Overall, our findings indicate that comparisons of incidence rates of statin use across time periods, population subgroups, and between studies using different statin-free periods should be done cautiously.
Our observations on the differences in cohort characteristics according to the definition of new use may have implications especially for studies assessing acute health outcomes of statin use. For example, when an inception cohort of statin initiators in 2007 is defined based on 1 year versus 3 or more years of no statin purchases, the cohort is more likely to include older women due to their greater chance of being misclassified. Consequently, for example, the estimates of relative risks of potential adverse events, such as a rise in liver enzymes and myopathies with the peak in incidence during the first year of treatment [27] , may be more biased in this than other population subgroups.
Our study has limitations. Despite their obvious generalizability to all ambulatory statin users in Finland and to those in other countries with similar health care and drug coverage systems, the results could be different in, for example, heterogenous North American populations with various prescription drug coverage plans [28] . Furthermore, we may have inadvertently misclassified statin use, persistence, and adherence for many reasons. First, we did not have data on hospitalizations nor is the drug use in hospital or other institutional care captured in the Register, potentially leading to an overestimation of gaps in statin use and underestimation of adherence. Second, we assumed that the dosage for all users was one tablet per day. Because of the splitting of tablets, we may have underestimated the adherence; however, the splitting of tablets would appear to be rare [29] . Conversely, prescribing dosages of more than one tablet per day would have led to overestimation of adherence and persistence. Finally, we approximated the patients' actual drug use based on dispensations, and therefore we could not be sure if and how the dispensed statins were used. Neither were we able to address the reasons why patients stopped or restarted their statin use [15, 30] .
In conclusion, statin use is dynamic and reinitiations after treatment gaps are common. This behavior should be taken into consideration in clinical practice and especially when studying the incidence, patterns, and health outcomes of statin use.
